scholarly journals Clinical profile, BRCA2 expression, and the androgen receptor CAG repeat region in Egyptian and Moroccan male breast cancer patients

2011 ◽  
Vol 33 (1) ◽  
pp. 17-26 ◽  
Author(s):  
Samuel F. Gilbert ◽  
Amr S. Soliman ◽  
Mehdi Karkouri ◽  
Meaghen Quinlan-Davidson ◽  
Ashley Strahley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Male Breast ◽  
Cag Repeat ◽  
Clinical Profile ◽  
Breast Cancer Patients ◽  
Repeat Region

scholarly journals Androgen receptor polyglutamine tract length in Egyptian male breast cancer patients

2011 ◽  
Vol 129 (2) ◽  
pp. 575-581 ◽  
Author(s):  
Samuel F. Gilbert ◽  
Amr S. Soliman ◽  
Maria Iniesta ◽  
Mohab Eissa ◽  
Ahmed Hablas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Male Breast ◽  
Breast Cancer Patients ◽  
Tract Length ◽  
Polyglutamine Tract

BRCA gene mutations in Slovenian male breast cancer patients

2007 ◽  
Vol 4 (03) ◽  
Author(s):  
N Besic ◽  
B Cernivc ◽  
J De Greve ◽  
K Lokar ◽  
M Krajc ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Gene Mutations ◽  
Male Breast ◽  
Breast Cancer Patients ◽  
Brca Gene

scholarly journals The role of adjuvant chemotherapy in stage I–III male breast cancer: a SEER-based analysis

2020 ◽  
Vol 12 ◽  
pp. 175883592095835
Author(s):  
Wei-Ping Li ◽  
Hong-Fei Gao ◽  
Fei Ji ◽  
Teng Zhu ◽  
Min-Yi Cheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Tumour Size ◽  
Male Breast ◽  
Stage I ◽  
Breast Cancer Patients ◽  
Chemotherapy Group

Background and aims: Male breast cancer is an uncommon disease. The benefit of adjuvant chemotherapy in the treatment of male breast cancer patients has not been determined. The aim of this study was to explore the value of adjuvant chemotherapy in men with stage I–III breast cancer, and we hypothesized that some male patients may safely skip adjuvant chemotherapy. Methods: Male breast cancer patients between 2010 and 2015 from the Surveillance Epidemiology and End Results database were included. Univariate and multivariate Cox analyses were used to analyse the factors associated with survival. The propensity score matching method was adopted to balance baseline characteristics. Kaplan–Meier curves were used to evaluate the impacts of adjuvant chemotherapy on survival. The primary endpoint was survival. Results: We enrolled 514 patients for this study, including 257 patients treated with chemotherapy and 257 patients without. There was a significant difference in overall survival (OS) but not in breast cancer-specific survival (BCSS) between the two groups ( p < 0.001 for OS and p = 0.128 for BCSS, respectively). Compared with the non-chemotherapy group, the chemotherapy group had a higher 4-year OS rate (97.5% versus 95.2%, p < 0.001), while 4-year BCSS was similar (98% versus 98.8%, p = 0.128). The chemotherapy group had longer OS than the non-chemotherapy group among HR+, HER2–, tumour size >2 cm, lymph node-positive male breast cancer patients ( p < 0.05). Regardless of tumour size, there were no differences in OS or BCSS between the chemotherapy and non-chemotherapy cohorts for lymph node-negative patients (OS: p > 0.05, BCSS: p > 0.05). Adjuvant chemotherapy showed no significant effects on both OS and BCSS in patients with stage I (OS: p = 0.100, BCSS: p = 0.858) and stage IIA breast cancer (OS: p > 0.05, BCSS: p > 0.05). Conclusion: For stage I and stage IIA patients, adjuvant chemotherapy could not improve OS and BCSS. Therefore, adjuvant chemotherapy might be skipped for stage I and stage IIA male breast cancer patients.

Detection and prevalence of disseminated tumor cells from the bone marrow of early stage male breast cancer patients

2015 ◽  
Vol 152 (1) ◽  
pp. 51-55 ◽  
Author(s):  
Andreas D. Hartkopf ◽  
Florin-Andrei Taran ◽  
Christina B. Walter ◽  
Markus Hahn ◽  
Tanja Fehm ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Male Breast Cancer ◽  
Early Stage ◽  
Disseminated Tumor Cells ◽  
Male Breast ◽  
Breast Cancer Patients

Prognostic Value of the Neutrophil-Lymphocyte, Platelet-Lymphocyte, and Monocyte-Lymphocyte Ratios in Male Breast Cancer Patients

Oncology ◽  
2020 ◽  
Vol 98 (7) ◽  
pp. 487-492
Author(s):  
Joanna Huszno ◽  
Zofia Kołosza ◽  
Jolanta Mrochem-Kwarciak ◽  
Aleksander Zajusz
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Male Breast Cancer ◽  
Prognostic Value ◽  
Male Breast ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document